| Pioglitazone: beyond glucose control. | |
| | |
MedLine Citation:
|
PMID: 20670183 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pioglitazone is an oral antidiabetic agent that decreases insulin resistance in adipose tissue, liver and muscles. This action is mediated by its link to a nuclear receptor called peroxisome proliferator-activated receptor-gamma. By improving insulin sensitivity, hepatic glucose production decreases and glucose uptake increases in the peripheral tissues. Beyond these effects on glucose metabolism, pioglitazone has positive effects on lipid metabolism, blood pressure, endothelial function, adiponectin and C-reactive protein levels. These make pioglitazone treatment effective beyond glucose control. In this article, current evidence concerning pioglitazone in the treatment of Type 2 diabetes will be reviewed. |
| | |
Authors:
|
Pedro de Pablos-Velasco |
Related Documents
:
|
12917943 - Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chir... 16298633 - Effects of insulin sensitizers on islet transplantation. 9839233 - Effect of overfeeding during the dry period on regulation of adipose tissue metabolism ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert review of cardiovascular therapy Volume: 8 ISSN: 1744-8344 ISO Abbreviation: Expert Rev Cardiovasc Ther Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-30 Completed Date: 2010-11-04 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101182328 Medline TA: Expert Rev Cardiovasc Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1057-67 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology & Diabetes and Metabolism, Dr Negrin Hospital, Las Palmas University, Spain. ppablos@dcmq.ulpgc.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipose Tissue
/
metabolism Administration, Oral Blood Glucose / drug effects Clinical Trials as Topic Diabetes Mellitus, Type 2 / drug therapy*, physiopathology Humans Hypoglycemic Agents / adverse effects, pharmacology* Insulin Resistance Liver / drug effects, metabolism Thiazolidinediones / adverse effects, pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Thiazolidinediones; 111025-46-8/pioglitazone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: News in brief.
Next Document: Update on the clinical development of cangrelor.